We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+4.84%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$704M
AUM Growth
+$37.8M
Cap. Flow
+$141M
Cap. Flow %
19.98%
Top 10 Hldgs %
44.68%
Holding
54
New
11
Increased
21
Reduced
11
Closed
7

Top Buys

Rank Stock Value
1
CNTX icon
Context Therapeutics
CNTX
+$25.4M
2
ZLAB icon
Zai Lab
ZLAB
+$22.2M
3
PTCT icon
PTC Therapeutics
PTCT
+$14.8M
4
SRRK icon
Scholar Rock
SRRK
+$13.6M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$11.7M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$16.3M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$15.4M
3
KALV
KalVista Pharmaceuticals
KALV
+$10.4M
4
VKTX icon
Viking Therapeutics
VKTX
+$7.66M
5
NTLA icon
Intellia Therapeutics
NTLA
+$5.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TWST icon
26
Twist Bioscience
TWST
$8.87B
$12.4M 1.76%
267,497
-27,433
-9% -$1.24M
CMPX icon
27
Compass Therapeutics
CMPX
$432M
$12.4M 1.76%
8,567,896
+2,926,002
+52% +$4.86M
JANX icon
28
Janux Therapeutics
JANX
$1.1B
$12.3M 1.75%
230,000
+58,895
+34% +$3.12M
REPL icon
29
Replimune Group
REPL
$1.46B
$11.5M 1.63%
+950,000
New +$11.5M
NUVB icon
30
Nuvation Bio
NUVB
$2.34B
$11.1M 1.57%
+4,164,178
New +$10.7M
VERA icon
31
Vera Therapeutics
VERA
$2.46B
$10.9M 1.55%
+257,788
New +$11.4M
IDYA icon
32
IDEAYA Biosciences
IDYA
$3.87B
$10.6M 1.51%
+414,035
New +$11.7M
RLAY icon
33
Relay Therapeutics
RLAY
$4.11B
$9.35M 1.33%
2,268,825
+235,784
+12% +$1.28M
UTHR icon
34
United Therapeutics
UTHR
$22.1B
$8.12M 1.15%
+23,000
New +$8.45M
ARCT icon
35
Arcturus Therapeutics
ARCT
$432M
$7.81M 1.11%
459,943
+240,435
+110% +$4.53M
XENE icon
36
Xenon Pharmaceuticals
XENE
$5.81B
$7.73M 1.1%
197,212
+31,412
+19% +$1.3M
STOK icon
37
Stoke Therapeutics
STOK
$2.04B
$7.56M 1.07%
685,826
+206,374
+43% +$2.54M
AQST icon
38
Aquestive Therapeutics
AQST
$630M
$5.74M 0.81%
1,611,833
-184,917
-10% -$853K
AXSM icon
39
Axsome Therapeutics
AXSM
$10.4B
$4.23M 0.6%
+50,000
New +$4.6M
STRO icon
40
Sutro Biopharma
STRO
$339M
$3.97M 0.56%
216,006
-67,200
-24% -$2.05M
HOWL icon
41
Werewolf Therapeutics
HOWL
$45.8M
$3.53M 0.5%
2,388,011
– –
DSGN icon
42
Design Therapeutics
DSGN
$946M
$3.45M 0.49%
+559,547
New +$3.24M
ZNTL icon
43
Zentalis Pharmaceuticals
ZNTL
$360M
$3.35M 0.48%
1,106,851
-358,950
-24% -$1.18M
VERU icon
44
Veru
VERU
$44.8M
$2.79M 0.4%
+428,537
New +$3.18M
ADAP
45
DELISTED
Adaptimmune Therapeutics
ADAP
$2.75M 0.39%
5,095,912
– –
ALXO icon
46
ALX Oncology
ALXO
$277M
$2.32M 0.33%
1,391,434
-1,018,428
-42% -$1.57M
RPTX
47
DELISTED
Repare Therapeutics
RPTX
$1.61M 0.23%
1,231,154
-408,695
-25% -$1.22M
ETNB
48
DELISTED
89bio
ETNB
– –
-330,000
Closed -$2.44M
KALV
49
DELISTED
KalVista Pharmaceuticals
KALV
– –
-896,915
Closed -$10.4M
MDGL icon
50
Madrigal Pharmaceuticals
MDGL
$12.3B
– –
-72,395
Closed -$15.4M
1
2
3

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q4 2024 Portfolio in Review

As of Q4 2024, MPM BioImpact held 54 positions worth $704M, up 5.7% from $667M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

MPM BioImpact deployed $141M of net new capital in Q4 2024, opening 11 new positions and adding to 21 existing holdings. Its largest new stake was Context Therapeutics: 14,705,882 shares worth $15.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Insmed, an estimated $16.3M trimmed.

  • MPM BioImpact's largest Q4 2024 buy was Context Therapeutics: 14,705,882 shares worth $15.4M.
  • MPM BioImpact added most to PTC Therapeutics in Q4 2024, an estimated $14.8M increase.
  • MPM BioImpact's biggest Q4 2024 reduction was Insmed, cutting an estimated $16.3M.
  • MPM BioImpact fully exited Madrigal Pharmaceuticals in Q4 2024, selling an estimated $15.4M.
  • MPM BioImpact's ten largest holdings make up 45% of its $704M portfolio in Q4 2024.
  • MPM BioImpact opened 11 new positions and closed 7 in Q4 2024.
  • MPM BioImpact's portfolio value rose 5.7% quarter-over-quarter to $704M.

Based on MPM BioImpact's 13F filing for Q4 2024, filed 14 Feb 2025.